Anxiety that does not respond to medication is not a character flaw. It is a clinical reality affecting tens of millions of adults across the United States. When SSRIs cause side effects, when benzodiazepines create dependency, or when therapy alone has not been enough, many patients in Woodland Hills and the San Fernando Valley are left wondering what comes next.
Dr. Kapustina reviews each patient’s complete treatment history during the intake evaluation at Iris TMS Wellness. She determines whether the clinical threshold for TRD has been met and which TMS protocol is most appropriate.
Find out whether TMS is right for your anxiety: verify your insurance benefits today at no cost and with no commitment.
No commitment required. Free, same-day response.
20300 Ventura Blvd, Suite 275
Medicare & Major Plans Accepted
Free In Building Lot
Free — No Obligation
Yes. TMS therapy reduces anxiety symptoms in a significant portion of patients who receive it, and the clinical evidence continues to grow. However, the precise way TMS applies to anxiety depends on the diagnosis.
TMS is FDA-approved for major depressive disorder (since 2008) and obsessive-compulsive disorder (since 2018). For other anxiety disorders, including generalized anxiety disorder (GAD), social anxiety, and panic disorder, TMS is used as an evidence-supported off-label treatment. Dozens of published clinical studies document measurable anxiety reduction with rTMS, and most patients who receive TMS for depression also experience concurrent, significant improvements in anxiety symptoms.
Anxious depression formally referred to as major depressive disorder with anxious distress is the most common clinical presentation at TMS clinics. In this condition, depression and anxiety exist simultaneously. The patient feels both hopeless and chronically tense, worried, or afraid.
TMS for anxious depression targets the left dorsolateral prefrontal cortex (DLPFC), the brain region most associated with both conditions. A 2024 study published in a leading psychiatry journal found that rTMS patients with anxious depression showed greater reductions in both depressive symptoms and anxiety compared to patients who received pharmacological treatment.
For patients with this overlapping presentation, TMS is one of the most effective interventions available because it addresses both conditions through the same treatment course.
Some patients carry a primary diagnosis of anxiety disorder without significant depression. For these patients, TMS is an evidence-supported clinical option, used off-label by trained clinicians based on the growing body of published research.
A 2022 systematic review and meta-analysis published in the International Journal of Neuropsychopharmacology found a robust effect of rTMS in patients with generalized anxiety disorder, concluding that TMS shows significant clinical benefit for GAD and calling for wider implementation.
A 2025 transdiagnostic study (Samokhvalov and Doomra) found that in complex clinical populations treated with rTMS, 53.5% experienced improvement in anxiety symptoms and 29.6% achieved complete resolution of anxiety.
Coverage depends on your diagnosis. Our team confirms your specific plan’s coverage before any treatment begins at no cost to you.
TMS works by delivering focused magnetic pulses to specific brain regions. For anxiety, understanding which regions are involved and why TMS affects them is clinically meaningful.
Anxiety is not simply a feeling. It is a pattern of abnormal neural activity across interconnected brain regions. Three areas are most consistently involved:
This region processes fear and threat. In people with chronic anxiety, the amygdala is overactive, responding to non-threatening situations as though they are dangerous.
This region regulates emotional responses and provides rational modulation of amygdala activity. In anxiety disorders, the prefrontal cortex shows reduced activity, meaning it cannot adequately suppress the overactive fear response.
This region coordinates attention, decision-making, and emotional regulation. It shows structural and functional abnormalities in multiple anxiety disorders.
Anxiety is self-reinforcing. Chronic worry activates the stress response. The stress response produces physical symptoms. Physical symptoms produce more worry. The cycle repeats.
TMS breaks this cycle at the neural level not through sedation or chemical suppression, but by changing the activity patterns in the brain regions that drive it. Repetitive TMS sessions cause neuroplastic changes: the brain adapts by strengthening the regulatory circuits and reducing the hyperreactivity in the fear circuits.
This mechanism is different from benzodiazepines, which chemically suppress anxiety symptoms but do not address the root neural patterns. It is also different from SSRIs, which work systemically and take weeks to months to affect anxiety through neurotransmitter modulation.
Generalized anxiety disorder affects an estimated 10% of adults in the United States at any given year. It is characterized by persistent, excessive worry about multiple domains of life, accompanied by physical symptoms including muscle tension, sleep disruption, fatigue, and concentration difficulties.
Many patients with GAD do not achieve full relief from SSRIs or SNRIs. A significant proportion cannot tolerate these medications due to side effects. For this population, rTMS targeting the left DLPFC provides an alternative pathway to symptom reduction that does not require ongoing pharmaceutical management.
The 2022 meta-analysis in the International Journal of Neuropsychopharmacology, which specifically reviewed rTMS for GAD, concluded that the evidence supports a clinically meaningful benefit, calling for larger randomized controlled trials to confirm and optimize the approach.
Social anxiety disorder and panic disorder both involve an overactive fear response to specific triggering situations. Social anxiety produces disproportionate fear of social evaluation and judgment. Panic disorder produces sudden, overwhelming physical symptoms of anxiety that feel indistinguishable from a cardiac event.
Both conditions involve the same prefrontal-amygdala circuit imbalance that TMS addresses. Clinical case reports and smaller studies document benefit in both conditions. For patients who have not responded to CBT, medication, or a combination of the two, TMS is a reasonable clinical next step that Dr. Kapustina can evaluate during the intake appointment.
Post-traumatic stress disorder produces anxiety, hypervigilance, intrusive thoughts, and emotional dysregulation tied to past trauma. It shares neural circuit abnormalities with both anxiety disorders and major depressive disorder.
Multiple published studies document significant PTSD symptom reduction with rTMS, including reductions in hyperarousal, avoidance, and intrusive re-experiencing. Many PTSD patients also carry a comorbid depression diagnosis, making TMS relevant to both conditions simultaneously.
At Iris TMS Wellness, neurofeedback therapy is also available for PTSD patients, particularly those whose trauma presentations involve strong physiological arousal components. Dr. Kapustina determines whether TMS, neurofeedback, or both are the right approach during the clinical evaluation.
OCD is an FDA-cleared indication for deep TMS, receiving clearance in 2018. Standard repetitive TMS also shows clinical benefit for OCD symptoms in published research. TMS for OCD targets different brain circuits than TMS for depression, focusing on the orbitofrontal cortex and the striatum, which are overactive in OCD.
For Iris TMS Wellness patients whose anxiety takes the form of intrusive thoughts and compulsive behaviors, Dr. Kapustina discusses the evidence base and appropriate TMS protocol during the intake evaluation.
The clinical evidence for TMS in anxiety has grown substantially in the past decade. Here is what the current published literature shows:
Samokhvalov & Doomra, 2025 (Transdiagnostic study): In complex clinical populations treated with rTMS, 53.5% of patients experienced improvement in anxiety symptoms and 29.6% achieved complete resolution of anxiety symptoms, alongside high depression improvement rates.
International Journal of Neuropsychopharmacology, 2022 (Meta-analysis): Found a robust clinical benefit of rTMS for generalized anxiety disorder, with results supporting its use as an adjunctive treatment option for GAD patients who have not responded to first-line therapies.
Dalhuisen et al., 2024: rTMS patients with treatment-resistant depression achieved greater reductions in both depressive symptoms and anxiety compared to patients who were switched to a different antidepressant medication or received pharmacological augmentation.
Sackeim et al., 2020 (Large real-world cohort, n=5,010): Response rates of 58% to 83% and remission rates of 28% to 62% across both depressive and anxiety outcome measures.
These findings are consistent with what Iris TMS Wellness patients experience clinically: anxiety symptoms typically begin to improve within 2 to 4 weeks of starting TMS, often lagging behind depression improvements by one to two weeks before catching up.
Not every anxiety patient is a candidate for TMS. Dr. Kapustina conducts a full clinical evaluation before recommending it.
You may be a strong candidate if:
You may not be a good candidate if you have:
Dr. Kapustina reviews your full medical history at the intake evaluation to confirm eligibility.
Your first appointment at Iris TMS Wellness is a clinical evaluation with Dr. Elena Kapustina, PsyD. It is not a TMS session. During this appointment:
Dr. Kapustina reviews your anxiety history, symptom pattern, and prior treatment experiences in detail. She assesses whether your anxiety is a standalone condition or part of a comorbid presentation with depression or PTSD. She discusses which treatment protocol is most appropriate: TMS, neurofeedback, or a combination of both.
The insurance team verifies your benefits during the same visit. You receive a written cost estimate before you agree to anything.
The TMS treatment schedule for anxiety is the same as the standard depression protocol: 30 to 36 sessions over six to seven weeks, five days per week. Each session lasts 20 to 40 minutes. Patients remain awake throughout and drive themselves to and from every session.
Most patients with anxious depression begin noticing changes in sleep, concentration, and physical tension within the first two to three weeks of treatment. Anxiety symptom improvements sometimes follow depression improvements by one to two weeks.
For patients with a more acute need, Dr. Kapustina may discuss an accelerated TMS protocol: a higher number of sessions delivered over a shorter period. Protocol selection is based on each patient’s clinical presentation.
There is no recovery period after each session. Patients from Woodland Hills, Tarzana, Calabasas, Encino, and throughout the San Fernando Valley schedule TMS sessions around their normal daily routines without disruption.
Every TRD patient at Iris TMS Wellness follows a structured four-stage process built around clinical clarity, insurance transparency, and personalized treatment design.
Your first appointment is a clinical evaluation, not a TMS session. Dr. Elena Kapustina, PsyD reviews your complete mental health history, all antidepressant trials with dosages and durations, any prior treatment attempts, and your current symptom presentation.
At the end of the evaluation, she gives you a direct clinical recommendation: whether TMS is appropriate for your TRD presentation, which protocol will be used, and what outcome you can reasonably expect based on your clinical history.
Iris TMS Wellness’s insurance team contacts your carrier before your first TMS session begins. The team confirms whether your plan covers TMS for your TRD diagnosis, what your out-of-pocket cost will be, and whether prior authorization is required.
For TRD patients, prior authorization typically requires documentation of the failed antidepressant trials, the diagnosis, and the treatment rationale. Iris TMS Wellness prepares and submits all required documentation. Most authorizations are confirmed within 5 to 10 business days.
Your treatment plan is built around your specific clinical presentation. Dr. Kapustina determines the coil placement, the stimulation parameters (frequency, intensity, pulse count), and the session schedule based on your individual motor threshold calibration and treatment history.
Patients with more severe or longstanding TRD may require a full 36-session course. Those with partial prior antidepressant response may show results earlier. The plan is adjusted throughout treatment based on your response.
Dr. Kapustina tracks your progress throughout the treatment course using structured symptom rating scales administered at regular intervals. If your response is slower than expected, the clinical team can adjust stimulation parameters or schedule additional monitoring.
Medicare covers TMS for patients with major depressive disorder who meet the clinical threshold for TRD. The Medicare definition requires at least one failed antidepressant trial at adequate dose and duration.
In 2026, Medicare Part B has an annual deductible of $283. After meeting the deductible, patients pay 20% coinsurance per session. Medicare covers the remaining 80%. Patients with Medigap supplemental coverage may owe $0 out of pocket for the full TMS course.
For seniors in Woodland Hills, Tarzana, Encino, Calabasas, and throughout the San Fernando Valley, TMS for treatment-resistant depression under Medicare is one of the most significant mental health benefits available today. Many seniors have been living with inadequately treated depression for years. TMS offers a covered, outpatient, drug-free path forward.
Some patients with treatment-resistant depression benefit from a combined approach: TMS addressing the neurological basis of depression directly, alongside neurofeedback addressing the self-regulatory patterns that depression has disrupted over time.
Neurofeedback uses real-time EEG monitoring to help patients observe and learn to shift their own brainwave patterns. For TRD patients who have lived with depression for years, the condition often creates deeply conditioned patterns of hyperactivated stress responses, disrupted sleep architecture, and impaired emotional regulation that extend beyond what TMS alone addresses.
Neurofeedback as a complement to TMS can support the recovery process by training the brain toward calmer, more regulated states during a period when the TMS is actively restoring prefrontal activity.
Iris TMS Wellness is one of the few practices in the San Fernando Valley offering both TMS and neurofeedback within the same clinic, under the same clinical supervision. For TRD patients whose presentations include significant anxiety, sleep disruption, or cognitive difficulties alongside depression, Dr. Kapustina determines during the intake evaluation whether a combined approach is clinically warranted.
This depends on your primary diagnosis and insurance plan. Here is the honest clinical and coverage picture.
Medicare and most major commercial insurance plans cover TMS for this presentation. The anxiety improvement is a documented secondary benefit of the same approved treatment course. Patients in this category have the clearest path to coverage.
Deep TMS has FDA clearance for OCD since 2018. Some commercial plans cover this. Medicare coverage for TMS specifically for OCD is less consistent than for MDD. Iris TMS Wellness verifies your specific plan’s OCD TMS coverage during benefits verification.
Coverage is less certain because TMS is not FDA-approved for these diagnoses as standalone conditions. Some commercial plans do cover TMS for anxiety based on clinical necessity. Medicare generally does not cover TMS unless an MDD diagnosis is also present.
Coverage for TMS anxiety treatment depends on your specific diagnosis and insurance plan. Our team investigates your specific plan and gives you a clear, accurate answer before you commit to anything.
No commitment required. Free, same-day response.
TMS is FDA-approved for major depressive disorder (2008) and obsessive-compulsive disorder (2018). For generalized anxiety disorder, social anxiety, and panic disorder, TMS is used as an evidence-supported off-label clinical treatment. Published research consistently shows significant anxiety reduction with rTMS, including a 2022 meta-analysis specifically for GAD and a 2025 transdiagnostic study showing 53.5% anxiety improvement in complex clinical populations.
TMS delivers focused magnetic pulses to the left dorsolateral prefrontal cortex (DLPFC), the brain region responsible for regulating emotional responses, including the fear and worry circuits that drive anxiety. Stimulating this region restores regulatory activity that is reduced in people with chronic anxiety, gradually reducing hypervigilance, worry, and physical tension over the treatment course.
Most patients begin noticing changes in anxiety symptoms within 2 to 4 weeks of starting TMS. In patients with both depression and anxiety, depression improvements often appear first, with anxiety following within one to two weeks. The full anxiety benefit typically develops over the complete 6 to 7 week treatment course.
For patients who want to reduce or discontinue benzodiazepines, TMS can be an appropriate adjunctive or transitional treatment. Any medication changes during TMS treatment are managed in coordination with the prescribing physician. Dr. Kapustina does not recommend abruptly stopping benzodiazepines but can advise on a clinical plan during the intake evaluation.
Yes. This is one of TMS’s most clinically significant advantages for patients with anxious depression. The same treatment course addresses both conditions simultaneously. A 2024 clinical study found that rTMS produced greater reductions in both depression and anxiety compared to medication switching in treatment-resistant patients.
Coverage depends on your primary diagnosis and insurance plan. TMS for anxiety as a standalone diagnosis has inconsistent coverage. TMS for major depressive disorder with anxiety features is covered by Medicare and most major commercial plans. Iris TMS Wellness verifies your specific coverage before you commit to treatment.
TMS actively stimulates the brain using magnetic pulses to restore regulatory neural activity. Neurofeedback teaches patients to self-regulate brainwave patterns using real-time EEG feedback. Both treat anxiety through different mechanisms and can be used together. TMS is insurance-covered for qualifying diagnoses. Neurofeedback is a cash-pay service. Dr. Kapustina determines the right approach during your evaluation.
Yes. Iris TMS Wellness evaluates patients with anxiety as their primary diagnosis, including GAD, social anxiety, PTSD, and OCD. Dr. Kapustina reviews the clinical evidence, your specific presentation, and your treatment history to determine whether TMS, neurofeedback, or a combination is the most appropriate option for your situation.